PUBLICATIONS
1. Stock RG, Mychalczak B, Armstrong JG, Curtin JP, Harrison LB:
The importance of brachytherapy technique in the treatment of primary carcinoma of the vagina. Int J Radiat Oncol Biol Phys.
24:747-753; 1992.
2. Stock RG, Chen ASJ, Flickinger JC, Kalnicki S, Seski J: Node positive cervical cancer: Impact
of pelvic irradiation and patterns of failure. Int J Radiat Oncol Biol Phys 31:31-36, 1995.
3. Stock RG, Chen ASJ,
Seski J: A thirty-year experience in the management of primary carcinoma of the vagina: Analysis of prognostic factors and
treatment modalities. Gynecol Oncol 56:45-52, 1995.
4. Stock RG, Stone NN, Wesson MF, DeWyngaert JK: A modified technique
allowing interactive ultrasound guided three- dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys.
32:219-225, 1995.
5. Stone NN, Ramin SA, Wesson MF, Stock RG, Unger P, Klein G: Laparoscopic pelvic lymph node dissection
combined with real time interactive transrectal ultrasound guided transperineal radioactive seed implantation of the prostate.
J Urol 153:1555-1560, 1995.
6. Unger PD, Hoon V, Stone NN, Liu Z, Theise N, Stock RG, Gil J: Computerized interactive
morphometry in the differential diagnosis of irradiated prostates - Anal Quant Cytol Histol 17:100-108,1995.
7. Stock
RG, Stone NN, Iannuzzi C, Unger P: Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection: Implications for
patient selection in the radiotherapeutic management of prostate cancer. Int J Radiat Oncol Biol Phys 33:815-821, 1995.
8. Stone NN, Stock RG, Iannuzzi CM, Unger P: Indications for seminal vesicle biopsy and laparoscopic pelvic lymph node
dissection in men with localized carcinoma of the prostate. J Urol 154:1392-1396, 1995.
9. Stone NN, Stock RG: Brachytherapy
for prostate cancer: Real- time three-dimensional interactive seed implantation. Tech Urol 1:72 -80, 1995.
10. Stone
NN, Stock RG, DeWyngaert JK, Tabert A: Prostate brachytherapy: Improvements in prostate volume measurements and dose distribution
using interactive ultrasound guided implantation and 3-D dosimetry. Radiat Oncol Investig 3:185-195, 1995.
11. Stock
RG: Locoregional therapies for early stage prostate cancer. Oncology 9:803-816, 1996.
12. Stock RG, Stone NN, Iannuzzi
C: Sexual potency following interactive ultrasound guided brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys
35:267-272, 1996.
13. Stock RG, Stone NN, DeWyngaert JK, Lavagnini P, Unger P: Prostate specific antigen findings
and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate cancer. Cancer
77:2386-2392, 1996.
14. Glajchen N, Shapiro R, Stock RG, Stone NN, Ramos R: CT findings following laparoscopic pelvic
lymph node dissection and radioactive seed implantation. Am J Roentgenol 166:1165-1168, 1996.
15. Stock RG, Chen
AS, Karasek K: Patterns of spread in node positive cervical cancer: The relationship between local control and distant metastases.
Cancer J Sci Am 2:256-262, 1996.
16. Linzer D, Stock RG, Stone NN, Iannuzzi C, Unger P: Seminal vesicle biopsy: Accuracy
and implications in patient selection in early stage prostate cancer. Urology 48:757-761, 1996.
17. Yeung N, Shapiro
RS, Glajchen N, Stock RG: CT appearance of the Syed-Neblett device for interstitial brachytherapy of gynecologic malignancies.
Comput Med Imaging Graph 20:403-406, 1996.
18. Stock RG, Terk M, DeWyngaert JK, Chan K, Stone NN, Dottino P: A new
technique for performing Syed-Neblett template interstitial temporary implants for gynecologic malignancies using transrectal
ultrasound guidance. Int J Radiat Oncol Biol Phys. 37:819-825, 1997.
19. Unger P., Wang Q, Gordon RE, Stock RG, Stone
NN: Localized amyloidosis of the seminal vesicle. Possible association with hormonally treated prostatic adenocarcinoma.
Arch Pathol Lab Med 121:1265-1268, 1997.
20. Stone NN, Stock RG, Unger P: Laparoscopic pelvic lymph node dissection
for prostate cancer: Comparison of the extended and modified techniques. J Urol 158:1891-1894, 1997.
21. Stock RG,
Stone NN: The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy. Semin Surg
Oncol 13:454-469, 1997.
22. Ferrari AC, Stone NN, Eyler JN, Gao M, Mandeli J, Unger P, Gallagher RE, Stock RG: Molecular
staging of pelvic lymph nodes increases the detection of micrometastases in high-risk localized prostate cancer patients.
J Natl Cancer Inst 89:1498-1504, 1997.
23. Stock RG, Dottino P, Jennings TS, Terk M, DeWyngaert K, Beddoe AM, Cohen
C: Enhanced radiosensitization with interferon alpha-2b and cisplatin in the treatment of locally advanced cervical carcinoma.
Gynecol Oncol 67:309-315,1997.
24. Baird M, Blasko J, Beyer D, Dattoli M, Grado G, Grimm P, Martinez A, Mate T, Nori
D, Porter A, Stock RG, Syed N, Wallner K: American Brachytherapy Society (ABS) survey of current clinical practice for permanent
brachytherapy of prostate cancer. Journal of Brachytherapy 13:243-251, 1997.
25. Stock RG, Stone NN, Tabert A, DeWyngaert
K: A dose response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 41:101-108, 1998.
26. Prestidge
BR, Prete JJ, Buchholz TA, Friedland JL, Stock RG, Grimm PD, Bice WS: A survey of current clinical practice of permanent prostate
brachytherapy in the United States. Int J Radiat Oncol Biol Phys 40:10001-5, 1998.
27. Prete JJ, Prestidge BR, Bice
WS, Friedland UL, Stock RG, Grimm PD: A survey of physics and dosimetry practice of permanent prostate brachytherapy in the
United States. Int J Radiat Oncol Biol Phys 39:1001-1009, 1998.
28. Stock RG, Stone NN, Yaghian P: Neoadjuvant androgen
suppression and permanent radioactive seed implant in the treatment of T1-T2 prostate cancer. Molecular Urology 2:121-127,
1998.
29. Terk MD, Stock RG, Stone NN: Identification of patients at an increased risk for prolonged urinary retention
following radioactive seed implantation of the prostate. J Urol 160:1379-1382, 1998.
30. Desai J, Stock RG, Stone
NN, Iannuzzi C, DeWyngaert JK: Acute urinary morbidity following I-125 interstitial implantation of the prostate gland. Radiat
Oncol Investig 6:135-141, 1998.
31. Stone NN, Stock RG, Parikh D, Unger P: Perineural invasion and seminal vesicle
involvement predict pelvic lymph node metastasis in men with localized pelvic carcinoma of the prostate. J Urol 160:1722-1726,
1998.
32. Stock RG, Ferrari AC, Stone NN: Does pelvic radiation play a role in the management of prostate cancer?
Oncology 12:1467-1472, 1998.
33. Lehrer S, Fodor F, Stock RG, Stone NN, Eng C, Song HK, McGovern M: Absence of 185delAG
mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer. Br J Cancer
78:771-773, 1998.
34. Stone NN, Stock RG: Laparoscopic pelvic lymph node dissection for prostate cancer. Mt Sinai
J Med 66:26-30, 1999.
35. Iannuzzi C, Stock RG, Stone NN: PSA kinetics following I-125 prostate seed implantation.
Radiat Oncol Investig 7:30-35, 1999.
36. Stone NN, Stock RG: Prostate brachytherapy: treatment strategies. J Urol
162:421-426, 1999.
37. Stock RG, Lo YC, Gaildon M, Stone NN: Does prostate brachytherapy treat the seminal vesicles?
A Dose Volume histogram analysis of seminal vesicles in patients undergoing combined PD-103 prostate implantation and external
beam irradiation. Int J Radiat Oncol Biol Phys 45:385-389,1999.
38. Green S, Stock RG, Greenstein A: Inflammatory
bowel disease and rectal cancer: Natural history and implication for radiation therapy. Int J Radiat Oncol Biol Phys 44:835-840,1999.
39. Stone NN, Stock RG: Neoadjuvant hormonal therapy improves outcomes of patients undergoing radioactive seed implant
for localized prostate cancer. Mol Urol 3:239-244,1999.
40. Stone NN, Stock RG: Dynamic cystography can replace cystoscopy
following prostate seed implantation. Tech Urol 6:112-116, 2000.
41. Nag S., Bice W., DeWyngaert JK, Prestidge B.,
Stock RG, Yu Y.: The American Brachytherapy Society recommendations for permanent prostate Brachytherapy post-implant analysis.
Int J Radiat Oncol Biol Phys. 46:221-230, 2000.
42. Stone NN, Stock RG: Prostate brachytherapy in patients with prostate
volumes 50cm3. Dosimetric analysis of implant quality. Int J Radiat Oncol Biol Phys 46:1199-204, 2000.
43. Stock
RG, Stone NN, Lo YC: Intraoperative dosimetric representation of the real-time ultrasound guided prostate implant. Tech Urol
6:95-98, 2000.
44. Stone NN, Ratnower E, Stock RG: Prostate brachytherapy: A prior transurethral resection does not
increase morbidity following the real-time seed implant method. Tech Urol 6:123-127, 2000.
45. Fang DX, Stock RG,
Machac J, Krynyckyi BR, Kim CK, Stone NN. The use of radioimmunoscintigraphy with 111-indium labeled CYT-356 (Prostascint)
scan in the evaluation of patients for salvage brachytherapy. Tech Urol 6:146-150, 2000.
46. Lehrer S, McCurdy L,
Stock RG, Stone NN, Ng CM. Body mass, age and the APC I1307K allele in Ashkenazi Jewish prostate cancer patients. Cancer
Genet Cytogenet 122:131-3, 2000.
47. Stock RG, Stone NN, Lo YC, Malhado N, Kao J, DeWyngaert JK. Post-implant dosimetry
for I-125 prostate implants: Definitions and factors affecting outcome. Int J Radiat Oncol Biol Phys 48:899-906, 2000.
48. Crawford ED, Batuello JT, Snow P, Gamito EJ, McLeod DG, Partin AW, Stone N, Montie J, Stock R, Lynch J, Brandt J.
The use of artificial intelligence technology to predict lymph node spread in men with clinically localized prostate cancer.
Cancer 88:2105-2109, 2000.
49. Stock RG, Stone NN, Kao J, Iannuzzi C, Unger P. The effect of disease and treatment
related factors on biopsy results following prostate brachytherapy: Implications for treatment optimization. Cancer 89:1829-34,
2000.
50. Stone NN, Stock RG, Unger P. Effect of neoadjuvant hormonal therapy on prostate biopsy results after I125
and Pd103 seed implantation. Mol Urol 4:163-170, 2000.
51. Stone NN, Stock RG, Unger P, Kao J. Biopsy results after
real-time ultrasound guided transperineal implants for stage T1-T2 prostate cancer. J Endourol 14: 375-380, 2000.
52. Stock
RG, Kao J, Stone NN. Penile erectile function following permanent radioactive seed implantation in the treatment of prostate
cancer. J Urol 165:436-9, 2001.
53. Snyder KM, Stock RG, Hong SM, Lo YC, Stone NN. Defining the risk of developing
grade 2 proctitis following I-125 prostate brachytherapy using a rectal dose volume histogram analysis. Int J Radiat Oncol
Biol Phys 50: 335-341, 2001.
54. Nag S, Ciezki JP, Cormack R, Dogget S, DeWyngaert K, Edmunson GK, Stock RG, Stone
NN, Yu Y, Zelefsky M. Intraoperative planning and evaluation of permanent prostate brachytherapy: Report of the American Brachytherapy
Society. Int J Radiat Oncol Biol Phys 51:1422-1430, 2001.
55. Atencio DP, Iannuzzi CM, Stock RG, Rosenstein BS. Screening
breast cancer patients for ATM mutations and polymorphisms using denaturing high performance liquid chromatography. Environ
Molec Mutagenesis 38:200-208, 2001.
56. Lehrer S, Diamond EJ, Stagger S, Stone NN, Droller MJ, Stock RG. Association
between serum triiodothyronine (t3) level and risk of disease recurrence in men with localized prostate cancer. Prost Ca Prost
Dis 4:232-234, 2001.
57. Lee L, Stock RG, Stone NN. The impact of hormonal therapy in the management of intermediate
to high risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 52:444-452,
2002.
58. Iannuzzi CM, Atencio DP, Green S, Stock RG, Rosenstein BS. ATM mutations in female breast cancer patients
predict for an increase in radiation-induced late effects. Int J Radiat Oncol Biol Phys 52:604-611, 2002.
59. Stock
RG, Stone NN. The importance post-implant dosimetry in permanent prostate brachytherapy. Eur Urol 41: 434-439, 2002.
60. Stone NN, Stock RG. Complications following permanent prostate brachytherapy. Eur Urol 41: 427-433, 2002.
61. Lehrer
S, Stone NN, Droller MJ, Stock RG. Association between American Urologic Association Urinary Symptom Score and disease stage
in men with localized prostate cancer. Urol Oncol 7:73 - 76, 2002.
62. Stock RG, Stone NN. Preliminary toxicity and
PSA response of a phase I/II trial of neoadjuvant hormonal therapy, Pd-103 brachytherapy and 3-D conformal external beam irradiation
in the treatment of locally advanced prostate cancer. Brachytherapy 1: 2 - 10, 2002.
63. Ferrari AC, Stone NN, Stock
RG, Bednar M, Essessee I, Singh H, Baldwin I, Mandeli J. 13 cis-retinoic acid (Isotretinoin) and complete androgen blockade
in advanced hormone naïve prostate cancer patients. Report of a phase II randomized study. J Clin Oncol 20: 538 - 544,
2002.
64. Stock RG, Stone NN, Dahlal M, Lo YC. What is the optimal dose for I-125 prostate implants? A dose response
analysis of biochemical control, post-treatment biopsies and long-term urinary symptoms. Brachytherapy 1: 83-89, 2002.
65. Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG. Increased serum insulin associated with increased risk of prostate
cancer recurrence. The Prostate 50: 1-3, 2002.
66. Nag S, Ellis RJ, Merrick GS, Bahnson R, Vicini F, Wallner K, Stock
R. American Brachytherapy Society recommendations for reporting morbidity following prostate brachytherapy. Int J Radiat
Oncol Biol Phys 54: 462-470, 2002.
67. Lehrer S, Diamond E, Stone NN, Droller M, Stock RG. Serum Triiodothyronine
(t3) is increased in men with prostate cancer and benign prostatic hypertrophy. J Urol 168: 2431-2433, 2002.
68. Lehrer
S, Diamond EJ, Stagger S, Stone NN, Stock RG. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason
score in prostate cancer. Br J Cancer 87: 726 - 728, 2002 .
69. Stock RG, Stone NN, Cesaretti J. Prostate specific
antigen bounce following prostate seed implantation for localized prostate cancer: Descriptions and implications. Int J Radiat
Oncol Biol Phys 56: 448-453, 2003.
70. Stone NN, Roy J, Lo YC, Stock RG. Prostate gland motion and deformation caused
by needle placement during brachytherapy. Brachytherapy 1: 154-160, 2002.
71. Lehrer S, Diamond EJ, Droller MJ, Stone
NN, Stock RG. Insulin -like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced stage prostate cancer.
JNCI 94: 1893-1894, 2002.
72. Lehrer S, Roboz J, Holland JF, Stone NN, Droller MJ, Stock RG. A 17.5 kda protein in
the serum of men with prostate cancer is increased in early stage. Br J Urol (in press).
73. Cesaretti J, Stone NN,
Stock RG. Urinary flare following prostate brachytherapy. Int J Radiat Oncol Biol Phys 56: 1085 - 1092, 2003.
74. Lehrer
S, Diamond E, Stone NN, Droller MJ, Stock RG, Stone M, Bajwa A, Kornreich R. Elevated serum triiodothyronine (t3) in Ashkenazi
Jewish prostate cancer patients carrying the I1307K allele of the APC (adenopolyposis coli) gene. Urol Oncol 21: 101-104,
2003.
75. Kollmeier MA, Stock RG, Stone N. Biochemical outcomes following prostate brachytherapy with minimum of
5 year follow-up: The importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys 57: 645 - 653, 2003.
76. Stone NN, Hong S, Lo YC, Howard V, Stock RG. Comparison of intraoperative dosimetric implant representation with
post-implant dosimetry in patients receiving prostate brachytherapy. Brachytherapy 2: 17-25, 2003.
77. Stone NN, Stock
RG. Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after I-125
prostate brachytherapy. Brachytherapy 2: 32-39, 2003.
78. Stone NN, Stock RG. Practical considerations in permanent
brachytherapy for localized adenocarcinoma of the prostate. Urol Clin North Am 30(2):351-62, 2003.
79. McNeely LK,
Stone NN, Pressoer J, Chircus JH, Stock RG. Influence of prostate volume on dosimetry results in real-time I1-25 seed implantation.
Int J Radiat Oncol Biol Phys 58: 292 - 299, 2004.
80. Lehrer S, Roboz J, Ding H, Zhao S, Diamond EJ, Holland JF,
Stone NN, Droller MJ, Stock RG. Putative protein markers in the sera of men with prostatic neoplasms. British J Urol 92: 223
- 225, 2003.
81. Stock RG, Cahlon C, Cesaretti JA, Kollmeier MA, Stone NN. Combined modality treatment in the management
of high-risk prostate cancer. Int J Radiat Oncol Biol Phys 59: 1352 - 1359, 2004.
82. Cesaretti JA, Stone NN, Stock
RG. Does prior transurethral resection of prostate compromise brachytherapy quality: a dosimetric analysis. Int J Radiat
Oncol Biol Phys. 60: 248-253, 2004.
83. Lehrer S, Stone NN, Stock RG. Prostate cancer in a large prostate is associated
with a decreased prostate specific antigen failure rate after brachytherapy. J Urol 173: 79-81,2005
84. Kollmeier
MA, Stock RG, Cesaretti J, Stone NN. Urinary morbidity following postbrachytherapy transurethral resection of the prostate.
J Urol 173:808-807, 2005.
85. Stone NN, Stock RG, Unger P. Intermediate-term Biochemical-free Progression and Local
Control Following I-125 Brachytherapy for Prostate Cancer. J Urol 173: 803-807.
86. Cesaretti JA, Stock RG, Lehrer
S, Atencio D, Bernstein JL, Stone NN, Wallenstein S, Loeb K, Kollmeier M, Smith M, Rosenstein B. ATM sequence variants are
predictive of adverse radiotherapy among patients treated for prostate cancer. Int J Radiat Oncol Biol Phys 61: 196-202, 2005.
87. Stone NN, Stock RG. Reduction of Pulmonary Migration of Permanent Interstitial Sources in Patients Undergoing Prostate
Brachytherapy" Urology 66: 119-123, 2005.
88. Lehrer S, Diamond EJ, Mamakind B, Droller M, Stone NN, Stock RG
C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer.
BJU Int 95(7):961-2, 2005.
89. Lehrer S, Diamond EJ, Stone NN, Stock RG. Serum thyroid-stimulating hormone is elevated
in men with Gleason 8 prostate cancer. BJU 96: 328-329, 2005.
90. Stock RG, Stone NN, Cesaretti JA, Rosenstein BS.
Biologically effective dose values for prostate brachytherapy: effects on PSA failure and post-treatment biopsy results.
Int J Radiat Oncol Biol Phys 64(2):527-33, 2006.
91. Stock RG, Cesaretti JA, Stone NN. Disease-specific survival
following the brachytherapy management of prostate cancer. Int J Radiat Oncol Biol Phys 64(3):810-6, 2006.
92. Crook
JM, Potters L, Stock RG, Zelefsky MJ. Critical organ dosimetry in permanent seed prostate brachytherapy: defining the organs
at risk. Brachytherapy. 2005;4(3):186-94.
93. Andreassen CN, Overgaard J, Alsner J, Overgaard M, Herskind C, Cesaretti
JA, Atencio DP, Green S, Formenti S, Stock RG, Rosenstein BS. ATM sequence variants and risk of radiation induced subcutaneous
fibrosis after post-mastectomy radiotherapy. Int J Radiat Oncol Biol Phys 64(3):776-83, 2006.
94. Ferrari AC, Stone
NN, Kurek R, Mulligan E, McGregor R, Stock R, Unger P, Tunn U, Kaisary A, Droller M, Hall S, Renneberg H, Livak KJ, Gallagher
RE, Mandeli J. Molecular load of pathologically-occult metastases in pelvic lymph nodes is an independent prognostic marker
of biochemical failure after localized prostate cancer treatment. J Clin Oncol 24(19):3081-8, 2006.
95. Peters C,
Cesaretti JA, Stone NN, Stock RG. Low-dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory
bowel disease. Int J Radiat Oncol Biol Phys 66(2):424-9, 2006.
96. Stock RG, Ho A, Cesaretti JA, Stone NN. Changing
the patterns of failure for high risk prostate cancer by optimizing local control. Int J Radiat Oncol Biol Phys 66(2):389-94,
2006.
97. Lehrer S, Cesaretti J, Stone NN, Stock RG. Urinary symptom flare after brachytherapy for prostate cancer
is associated with erectile dysfunction and increased pre-implant urinary symptoms. BJU Int. 98(5):979-81, 2006.
98. Zagar
TM, Stock RG, Cesaretti JA, Stone NN. Assessment of post-brachytherapy sexual function: a comparison of the IIEF-5 and the
MSEFS. Brachytherapy 6(1):26-33, 2007.
99. Ho A, Burri R, Cesaretti JA, Stone NN, Stock RG. Is seminal vesicle implantation
with permanent sources possible? A dose-volume histogram analysis in patients undergoing combined Pd-103 implantation and
external beam radiation for T3c prostate cancer. Brachytherapy 6(1):38-43, 2007.
100. Stone NN, Stock RG. Long-term
urinary, sexual and rectal morbidity in patients treated with I-125 prostate brachytherapy followed for a minimum of 5 years.
Urology 69: 338-342, 2007
101. Schiff JD, Bar Chama N, Cesaretti J, Stock R. Early use of a phosphodiesterase inhibitor
after brachytherapy restores and preserves erectile function. BJU 98:1255, 2006.
102. Frank SJ, Grimm PD, Sylvester
JE, Merrick S, Davis BJ, Zietman A, Moran BJ, Beyer DC, Roach M, Clark DH, Stock RG, Lee WR, Michalski JM, Wallner KE, Hurwitz
M, Potters L, Kuban DA, Prestidge BR, Vera A, Hathaway S, Blasko JC. Interstitial implant alone or in combination with external
beam radiation therapy for intermediate - risk prostate cancer: A survey of practice patterns in the United States. Brachytherapy
6: 2-8.
103. Stone NN, Stock RG. The effect of brachytherapy, external beam irradiation, and hormonal therapy on
prostate volume. J Urol 177: 1925-1928, 2007.
104. Ho AY, Atencio DP, Peters S, Stock RG, Formenti SC, Cesaretti
JA, Green S, Haffty B, Drumea K, Leitzin L, Kuten A, Azria D, Ozsahin M, Overgaard J, Andreassen CN, trop CS, Park J, rosenstein
BS.Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):646-55.
105. Cesaretti JA, Stock RG, Atencio DP, Peters S, Peters CA, Burri RJ, Stone NN, Rosenstein BS. A genetically determined
dose response relationship predicts for rectal bleeding among patients treated with prostate brachytherapy. Int J Radiat Oncol
Biol Phys Int J Radiat Oncol Biol Phys. 2007 ;68:1410-6.
106. Cesaretti JA, Stock RG, Stone NN. Impact of low dose
rate prostate brachytherapy on the sexual health of 131 men with optimal pre-treatment sexual function: an analysis at seven
year minimal follow-up. BJU Int. 2007 ;100:362-367.
107. Ho AY, Fan G, Atencio DP, Green S, Formenti S, Haffty BG,
Iyengar P, Bernstein JL, Stock RG, Cesaretti JA, Rosenstein BS. Possession of ATM Sequence Variants as a Predictor for Late
Normal Tissue Responses in Breast Cancer Patients Treated with Radiotherapy. Int J Radiat Oncol Biol Phys Int J Radiat Oncol
Biol Phys 2007 69:677-684.
108. Stone NN, Potters L, Davis BJ, Ciezki JP, Zelefsky MJ, Roach M, Fern PA, Kattan MW,
Stock RG. Customized dose prescriptions for permanent prostate brachytherapy: Insights from a multicenter analysis of dosimetry
outcomes. In J Radiat Oncol Biol Phys 2007 69: 1472 - 1477.
109. Stone NN, Stock RG, White I, Unger P. Patterns of
local failure following prostate brachytherapy. J Urol 177 :1759-63; 2007
110. Kao J, Stone NN, Lavaf A, Dumane V,
Cesaretti JA, Stock RG. (125)I monotherapy using D90 implant doses of 180 Gy or greater. Int J Radiat Oncol Biol Phys. 2008;
70:96-101.
112. Peters CA, Stock RG, Cesaretti JA, Atencio DP, Peters S, Burri R, Stone NN, Osterer H, Rosenstein
BS. TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated
with radiotherapy. Int J Radiat Oncol Biol Phys. 2008 70:752-759.
113. Stock RG, Cesaretti JA, Stone NN. Distant
and local recurrence in patients with biochemical failure following prostate brachytherapy. Brachytherapy 7: 217-222, 2008.
114. Peters C, Stock RG, Blacksburg S, Stone NN,. The Effect of Family History on Outcome in Patients Treated with Definitive
Brachytherapy for Clinically Localized Prostate Cancer. . Int J Radiat Oncol Biol Phys 2009; 73: 24-29.
115. Stone
NN, Potters L, Davis BJ, Ciezki JP, Zelefsky MJ, Roach M, Fern PA, Kattan MW, Stock RG. Multicenter Analysis of Impact of
High Biological Effective Dose (BED) on Biochemical Failure and Survival Outcomes in Patients with Gleason score 7-10 Prostate
Cancer Treated by Permanent Prostate Brachytherapy. . Int J Radiat Oncol Biol Phys 2009; 73: 1472-1477.
116. Burri
RJ, Stock RG, Cesaretti JA, Atencio DP, Peteres S, Peters CA, Fan G, Stone NN, Rosenstein BS. Association of single nucleotide
polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy
for prostate cancer. Radiation Research 170: 49-59. 2008.
117. Solan A, Cesaretti JA, Stone NN, Stock RG. There is
No Correlation Between Erectile Dysfunction and Dose to Penile Bulb and Neurovascular Bundles Following Real-Time Low-Dose
Rate Prostate Brachytherapy International Journal of Radiation Oncology, Biology, Physics. . Int J Radiat Oncol Biol Phys
2009; 73: 1468 - 1474.
118. Lehrer S, Montazema A, Ramanathan L, Pessin - Minsleym, Pfail J, Stock RG, Kogan R. Normal
serum bone markers in bisphosphonate induced osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endod
106: 389-391, 2008
119. Stock RG, Klein TJ, Cesaretti JA, Stone NN. Prognostic Significance of the 5-Year PSA Value
for Predicting Prostate Cancer Recurrence Following Brachytherapy Alone and in Combination with Hormonal Therapy and/or External
Beam Irradiation . Int J Radiat Oncol Biol Phys 2009: 74: 753-758.
120. Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock
RG. Radiation dose predicts for biochemical control in intermediate risk prostate cancer patients treated with low dose rate
brachytherapy. Int J Radiat Oncol Biol Phys 2009 :75: 16-22.
121. Kao J, Packer S, Linh Vu H, Schwartz ME, Sung MW,
Stock RG, Lo YC, Huang D, Chen SH, Cesaretti JA. Phase I study of concurrent sunitinib and image-guided radiotherapy followed
by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer 2009: 115: 3571-3580.
122. Stock RG, Cesaretti JA, Hall SJ, Stone NN. Outcomes for patients with high grade prostate cancer treated with a combination
of brachytherapy, external beam radiotherapy and hormonal therapy. BJUI 2009: 104; 1631 -1636.
123. Lehrer S, Montazem
A, Ramanathan L, Pessin-Minsley M, Pfail J, Stock RG, Kogan R. Bisphosphonate-induced osteonecrosis of the jaws, bone markers,
and a hypothesized candidate gene. J Oral Maxillofac Surg. 2009 Jan;67(1):159-61.
124. Potters L, Roach M 3rd, Davis
BJ, Stock RG, Ciezki JP, Zelefsky MJ, Stone NN, Fearn PA, Yu C, Shinohara K, Kattan MW. Postoperative Nomogram Predicting
the 9-Year Probability of Prostate Cancer Recurrence After Permanent Prostate Brachytherapy Using Radiation Dose as a Prognostic
Variable. Int J Radiat Oncol Biol Phys. 2009 Jun 17.
125. Burri R, Stone NN, Stock RG. Long term outcomes and toxicity
of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2009:
77; 1338 - 1344.
126. Burri R, Ho A, Stone NN, Stock RG . Young Men Have Equivalent Biochemical Outcomes Compared
To Older Men After treatment With Brachytherapy For Prostate Cancer. Int J Radiat Oncol Biol Phys 2010: 77; 1315 - 1321.
127. Stone NN, Stock RG, Cesaretti JA, Unger P. Local Control Following Permanent Prostate Brachytherapy: Effect of High
Biologically Effective Dose on Biopsy Results and Oncologic Outcomes. Int J Radiat oncol Biol Phys 2010 : 76; 355 - 360.
128. Stock RG, Yamalachi S, Hall SJ, Sone NN. Impact of Hormonal Therapy on Intermediate Risk Prostate Cancer Patients
treated with Combination Brachytherapy and External Beam Irradiation. J Urol 2010: 183; 546 - 550.
129. Stone NN,
Stock RG. Do high radiation doses in locally advanced prostate cancer patients treated with Pd-103 implant plus external
beam irradiation cause increased urinary, rectal and sexual morbidity. Brachytherapy 2010: 9; 114-118.
130. Stone
NN, Marshal D, Cesaretti JA, Stock RG. Does neoadjuvant hormonal therapy improve urinary function when given to men
with large prostates undergoing prostate brachytherapy? J Urol 2010: 183; 546 - 550.
131. Kerns S, Ostrer H, Stock
R, William Li, Moore J, Pearlman A, Campell C, Shao Y, Stone, N, Kusnetz L, Rosenstein B. Genome wide association study
to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African American
men following radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1292-300.
132. Carpenter
TJ, Forsythe K, Kao J, Stone NN, Stock RG. Outcomes for patients with extracapsular prostate cancer treated with trimodality
theapy, including brachytherapy, external beam radiotherapy and hormonal therapy. Brachytherapy. 2011 Jul-Aug;10(4):261-8.
133. Forsythe K, Burri R, Stone N, Stock RG. Predictors of Metastatic Disease After Prostate Brachytherapy. Int J Radiat
Oncol Biol Phys. 2012 Jun 1;83(2):645-52. Epub 2011 Dec 2.
134. Stone NN, Gerber NK, Blacksburg S, Stone J, Stock
RG. Factors Influencing Urinary Symptoms 10 Years After Permanent Prostate Seed Implantation. J Urol. 2012 Jan;187(1):117-23.
Epub 2011 Nov 23.
135. Forsythe K, Blacksburg S, Stone N, Stock RG.Intensity-Modulated Radiotherapy Causes Fewer Side
Effects than Three-Dimensional Conformal Radiotherapy When Used in Combination with Brachytherapy for the Treatment of Prostate
Cancer. Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):630-5. Epub 2011 Nov 16.
136. Ko EC, Stone NN, Stock RG.
PSA Nadir of <0.5 ng/mL Following Brachytherapy for Early-Stage Prostate Adenocarcinoma is Associated with Freedom from
Prostate-Specific Antigen Failure. Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):600-7. Epub 2011 Oct 8.
137. Yamoah
K, Stone N, Stock R. Impact of race on biochemical disease recurrence after prostate brachytherapy Cancer. 2011 Dec 15;117(24):5589-600.
138. Stone NN, Stone MM, Rosenstein BS, Unger P, Stock RG. Influence of pretreatment and treatment factors on intermediate
to long-term outcome after prostate brachytherapy.J Urol. 2011 Feb;185(2):495-500.
139. Stock RG, Berkowitz J, Blacksburg
SR, Stone NN. Gleason 7 prostate cancer treated with low dose rate brachytherapy: Lack of impact of primary Gleason pattern
on biochemical failure. BJU Nov;110(9):1257-61. doi: 10.1111/j.1464-410X.2012.11057.x. Epub 2012 May 9.
140. Grimm
P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Keyes M, Kupelian P, Lee WR, Machtens S, Mayadev J, Moran BJ, Merrick
G, Millar J, Roach M, Stock R, Shinohara K, Scholz M, Weber E, Zietman A, Zelefsky M, Wong J, Wentworth S, Vera R, Langley
S. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk
prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.BJU Int. 2012 Feb;109 Suppl
1:22-9. :
141. Snyder KM, Stock RG, Buckstein M, Stone NN. Long-term potency preservation following brachytherapy
for prostate cancer. BJU Int. 2012 Jul;110(2):221-5.
142. Buyyounouski MK, Davis BJ, Prestidge BR, Shanahan TG,
Stock RG, Grimm PD, Demanes DJ, Zaider M, Horwitz EM. A survey of current clinical practice in permanent and temporary prostate
brachytherapy: 2010 update.Brachytherapy. 2012 11: 299-303.
143. Stone NN, Skouteris VM, Stock RG. Biopsy and implantation
of the seminal vesicles. Brachytherapy. 2012 Sep-Oct;11(5):334-40. doi: 10.1016/j.brachy.2011.12.008. Epub 2012 Feb 2.
144. Davis BJ, Horwitz EM, Lee WR, Crook JM, Stock RG, Merrick GS, Butler WM, Grimm PD, Stone NN, Potters L, Zietman AL,
Zelefsky MJ. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy.
Brachytherapy. 2012 Jan;11(1):6-19.
145. Diefenbach MA, Mohamed NE, Butz BP, Bar-Chama N, Stock R, Cesaretti J, Hassan
W, Samadi D, Hall SJ. Acceptability and preliminary feasibility of an internet/CD-ROM-based education and decision program
for early-stage prostate cancer patients: randomized pilot study. J Med Internet Res. 2012 Jan 13;14(1):e6.
146. Tong
C, Ko EC, Sung MW, Cesaretti JA, Stock RG, Packer SH, Forsythe K, Genden EM, Schwartz M, Galsky M, Junko O. Phase II Trial
of Concurrent Sunitinib and Image-Guided Radiotherapy for Oligometastases. Plos One 2012;7(6):e36979. Epub 2012 Jun 27
147. Buckstein M, Kerns S, Forsythe K, Stone NN, Stock RG. Temporal Patterns of Selected Late Toxicities in Patients Treated
with Brachytherapy or Brachytherapy Plus External Beam Radiation for Prostate Adenocarcinoma. BJU 2012 Oct 9. doi: 10.1111/j.1464-410X.2012.11436.x.
[Epub ahead of print]
148. Buckstein M, Stone NN, Stock RG. Long Term Outcomes and Toxicity in Patients Treated with
Brachytherapy for Prostate Adenocarcinoma Younger than 60 Years of Age at Treatment with Minimum 10 Years Follow Up. Urology.
2013 Feb;81(2):364-8
149. Leapman M, Hall SJ, Stone N, Stock R. Hematuria after prostate brachytherapy. BJU Int.
2013 Jun;111(8):E319-24.
150. Kerns Sl, Stock R, Stone N, Buckstein M, Shao Y, Campbell, Rath L, DeRuyssher D, Lammering
G, Hixson R, Cesaretti J, Terk M, Ostrer H, Rosenstein B. A Two stage genome wide association study to identify nucleotide
polymorphisms associated with development of erectile dysfunction following radiotherapy for prostate cancer. IJROBP 2012
Sep 26. doi:pii: S0360-3016(12)03389-5. 10.1016/j.ijrobp.2012.08.003. [Epub ahead of print]
151. Kerns SL, Stone NN,
Stock RG, Rath L, Ostrer H, Rosenstein BS. A two stage genome wide association study to identify single nucleiotide polymorphisms
asoaciated with development of urinary symptoms following radiotherapy for prostate cancer. l J Urol. 2013 Jul;190(1):102-8
152. Stone NN, Stock RG. Prostate brachytherapy in men with gland volume of 100cc or greater: Technique, cancer control
and morbidity. Brachytherapy Brachytherapy. 2013 May-Jun;12(3):217-21
153. Price JG, Stone NN, Stock RG. Predictive
factors and management of rectal bleeding side effects following prostate cancer brachytherapy. Int J Radiat Oncol Biol Phys.
2013 Aug 1;86(5):842-7
154. Stock RG, Buckstein M, Liu JT, Stone NN. The relative importance of hormonal therapy and
biological effective dose in optimizing prostate brachytherapy treatment outcomes. BJU Int. 2013 Jul;112(2):E44-50.
155.
Marshall RA, Buckstein M, Stone NN, Stock R. Treatment outcomes and morbidity following definitive brachytherapy with or without
external beam radiation for the treatment of localized prostate cancer: 20-Year experience at Mount Sinai Medical Center.
Urol Oncol. 2013 Jun 12. doi:pii: S1078-1439(13)
156. Kerns SL, Stock RG, Stone NN, Blacksburg SR, Rath L, Vega A,
Fachal L, Gómez-Caamaño A, De Ruysscher D, Lammering G, Parliament M, Blackshaw M, Sia M, Cesaretti J, Terk
M, Hixson R, Rosenstein BS, Ostrer H. Genome-wide association study identifies a region on chromosome 11q14.3 associated with
late rectal bleeding following radiation therapy for prostate cancer.Radiother Oncol. 2013 Jun;107(3):372-6.
157.
Mock S, Leapman M, Stock RG, Hall SJ, Stone NN. Risk of Urinary Incontinence Following Post-Brachytherapy Transurethral Resection
of the Prostate and Correlation with Clinical and Treatment Parameters. J Urol. 2013 Nov;190(5):1805-181
158. Leapman
MS, Stock RG, Stone NN, Hall SJ. Findings at Cystoscopy Performed for Cause After Prostate Brachytherapy. Urology. 2014 Apr
3. pii: S0090-4295(14)00111-3. doi: 10.1016/j.urology.2014.01.031. [Epub ahead
159. Stone NN, Stock RG. 15-Year Cause
Specific and All-Cause Survival Following Brachytherapy for Prostate Cancer: Negative Impact of Long-term Hormonal Therapy.
J Urol. 2014 Mar 31. pii: S0022-5347(14)03182-6. doi: 10.1016/j.juro.2014.03.094. [Epub ahead of
160. Zelefsky MJ,
Shasha D, Branco RD, Kollmeier M, Baser RE, Pei X, Ennis R, Stock R, Bar-Chama N, Mulhall JP. Prophylactic Sildenafil Citrate
Improves Selected Aspects of Sexual Function in Men Treated by Radiotherapy for Prostate Cancer. J Urol. 2014 Mar 3. pii:
S0022-5347(14)00355-3. doi: 10.1016/j.juro.2014.02.097. [Epub ahead of
161. Stone NN, Unger Crawford ED, Stock RG.
Diagnosis and management of local recurrence after low-dose rate brachytherapy. Brachytherapy 2014: 1538-4721 (epub ahead
of print)
162. Ko EC, Liu JT, Stock RG. Association of early PSA failure time with increased distant metastasis and
decreased survival in prostate brachytherapy patients. Raditherapy Oncology 2014:110 261-267.
